Innovacell
Innovacell is a Tokyo-based, pre-revenue biotechnology company developing three autologous cell therapy pipelines for fecal and urinary incontinence, with lead candidate ICEF15 in Phase III trials and GMP manufacturing based at its Austrian subsidiary.
- Company typePublic
- Founded2000
- HeadquartersTokyo, Japan
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Innovacell does
Innovacell Inc. (イノバセル株式会社) is a Tokyo-headquartered biotechnology company developing autologous cell therapy products for the treatment of fecal and urinary incontinence. The company is advancing three distinct autologous cell therapy pipelines in the incontinence domain, with lead candidate ICEF15 currently in Phase III clinical trials. Core manufacturing technology is cultivated at the wholly-owned Austrian subsidiary Innovacell GmbH, whose GMP facility was the first located outside Asia to receive Specified Cell Processing Product Manufacturing Certification under Article 39, Paragraph 1 of Japan's Act on the Safety of Regenerative Medicine.
The company's business model focuses on discovering and developing cell therapy seeds globally for worldwide commercialization of regenerative medicine products. Distribution is planned through medical institutions and healthcare providers specializing in incontinence treatment once products receive regulatory approval. Innovacell is pre-revenue and recorded net losses in the fiscal year ending December 2024, consistent with its clinical-stage development status and 1–10 employee headcount.
Innovacell completed its initial public offering on the Tokyo Stock Exchange Growth Market on February 24, 2026, with Nomura Securities as lead underwriter and SBI Securities as participating underwriter. The offering of approximately 9.13 million shares at a JPY 1,290–1,350 indicative price range targeted gross proceeds of approximately JPY 12.32 billion (US$78 million) at a market capitalization of approximately US$280 million, providing capital to advance the clinical pipeline and prepare for commercialization.
Innovacell firmographics
Firmographics- Name
- Innovacell
- Legal name
- イノバセル株式会社 (Innovacell Inc.)
- Website
- https://innovacell.co.jp
- Company type
- Public
- Founded year
- 2000
- Operating status
- Ipo
- Headcount range
- 11–50 employees
- Short description
- Innovacell is a Tokyo-based, pre-revenue biotechnology company developing three autologous cell therapy pipelines for fecal and urinary incontinence, with lead candidate ICEF15 in Phase III trials and GMP manufacturing based at its Austrian subsidiary.
- Ownership category
- akta.pro rank
Innovacell industry classification
Industry- Product category
- Regenerative Medicine
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cell Therapy Developers (Autologous) (HLAAABAA)
- akta.pro secondary industries
- Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC), Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring) (HLAAABAJ), Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)
Keywords
Where Innovacell is headquartered
LocationHeadquarters
- HQ city
- Tokyo
- HQ country
- Japan
- HQ region
- Asia
Offices1 record
Markets served
Innovacell business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Cell Therapy Products: Pre-revenue stage biotechnology company developing regenerative medicine products for incontinence treatment. The company recorded net losses in fiscal year ending December 2024 while continuing R&D activities. Plans to commercialize cell therapy products globally.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Innovacell product offering
Product offeringCore offering
Innovacell discovers and develops autologous cell therapy products (regenerative medicine products) sourced globally, targeting fecal and urinary incontinence. The company has three pipeline candidates, with ICE-F15 being the most advanced in Phase III clinical trials. Manufacturing is conducted at its wholly-owned subsidiary Innovacell GmbH's GMP facility in Austria, with the intention to commercialize approved products globally through medical institutions.
Product overview
Innovacell is a biotechnology company developing three autologous cell therapy pipelines for treating fecal and urinary incontinence. The company operates using a business model that discovers and develops cell therapy products (regenerative medicine products) globally, with manufacturing capabilities at its Austrian subsidiary Innovacell GmbH. The core offering consists of three distinct cell therapy pipelines targeting the incontinence domain, with ICE-F15 being the most advanced candidate currently in Phase III clinical trials.
Differentiator
Problem solved
Functional benefit
Products and services
- Autologous Cell Therapy for Fecal Incontinence An autologous cell therapy pipeline candidate targeting fecal incontinence, developed using Innovacell's GMP manufacturing technology to restore continence and improve patient quality of life. Intended for distribution through medical institutions upon regulatory approval.
- Autologous Cell Therapy for Urinary Incontinence An autologous cell therapy pipeline candidate targeting urinary incontinence, utilizing cell-based regenerative medicine technology to treat patients suffering from incontinence. Intended for distribution through medical institutions upon regulatory approval.
- ICE-F15 Autologous Cell Therapy Innovacell's most advanced autologous cell therapy product candidate, currently in Phase III clinical trials, targeting fecal and urinary incontinence. Represents the company's lead clinical-stage asset toward commercial launch.
Companies that use Innovacell
Customer profileSegments1 record
Ideal customer profiles1 record
Innovacell technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Innovacell partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Innovacell GmbHcoreInnovacell GmbH based in Austria operates the GMP manufacturing facility that provides the manufacturing technology for the company. This facility was the first outside Asia to receive Japanese regulatory certification for cell processing.
Scale indicators6 records
Recent moves7 records
Expansion highlights5 records
Innovacell competitors and assessment
Company assessmentDirect peers
- Cook MyoSite (Cook Medical): Cook Medical's Cook MyoSite subsidiary develops autologous muscle-derived cell therapies for fecal and urinary incontinence. Directly comparable to Innovacell in target indication, autologous cell therapy modality, and clinical-stage status.
- Vericel Corporation: Vericel develops and commercializes autologous cell therapies (MACI, Epicel) for orthopedic and burn indications. Comparable as a publicly listed autologous cell therapy developer with regulatory approval and commercial infrastructure.
Emerging players
- Capricor Therapeutics: Clinical-stage cell therapy company developing allogeneic and autologous cell therapies for rare diseases. Comparable cell therapy pipeline-stage profile and therapeutic-area focus on underserved indications.
- BrainStorm Cell Therapeutics: Cell therapy company developing autologous cell treatments for neurodegenerative diseases. Comparable as a late-clinical-stage autologous cell therapy developer targeting high-unmet-need indications.
- Mesoblast Limited: Cell therapy company commercializing stem cell treatments for inflammatory and cardiovascular diseases. Comparable cell therapy commercialization profile and pipeline-stage profile.
- Athersys / Healios K.K. Healios is a Japanese regenerative medicine company developing stem cell therapies and partnering with Athersys on MultiStem. Comparable Japan-listed cell therapy developer with regulatory familiarity in the Japanese regenerative medicine framework.
- MediWound Ltd. Regenerative medicine company focused on wound care and tissue repair using biological therapies. Comparable as a publicly listed regenerative medicine developer with FDA and EMA-approved products.
Broad incumbents
- Organogenesis Holdings: Commercial-stage regenerative medicine company marketing cell-based and tissue-based products for wound care and surgical applications. Comparable regenerative medicine commercialization profile with broader product portfolio.
- Integra LifeSciences: Large medical device and regenerative tissue company with products in wound care, surgical, and tissue regeneration. Comparable as a broader regenerative medicine incumbent with established commercialization.
- Smith+Nephew: Global medical device company with a significant regenerative medicine and advanced wound management portfolio. Comparable broad incumbent with global commercial reach across tissue repair and regenerative categories.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Innovacell social profiles
Digital presenceInnovacell compliance and trust
Trust signalCompliance1 record
Innovacell financial estimates
Financial estimateRevenue estimate
Valuation estimate
Innovacell leadership team
Management profileNumber of profiles
Innovacell subsidiaries and ownership
Company hierarchySubsidiaries1 record
Innovacell funding detail
Funding detailFunding overview
Funding rounds14 records
Investors19 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Innovacell M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Innovacell
What does Innovacell do?
Innovacell discovers and develops autologous cell therapy products (regenerative medicine products) sourced globally, targeting fecal and urinary incontinence. The company has three pipeline candidates, with ICE-F15 being the most advanced in Phase III clinical trials. Manufacturing is conducted at its wholly-owned subsidiary Innovacell GmbH's GMP facility in Austria, with the intention to commercialize approved products globally through medical institutions.
Is Innovacell a public or private company?
Innovacell is a public company. It is classified as public and is currently ipo.
When was Innovacell founded?
Innovacell was founded in 2000. It employs 11 to 50 people.
Where is Innovacell based?
Innovacell is headquartered in Tokyo, Japan, in the Asia region.
How does Innovacell make money?
One revenue line is on record: cell Therapy Products.
Who are Innovacell's main competitors?
Direct peers on record are Cook MyoSite (Cook Medical) and Vericel Corporation. Emerging players are Capricor Therapeutics, BrainStorm Cell Therapeutics, Mesoblast Limited, Athersys / Healios K.K. and MediWound Ltd.. Broad incumbents are Organogenesis Holdings, Integra LifeSciences and Smith+Nephew.
Does Innovacell have an API?
No public API is recorded for Innovacell.
What industry is Innovacell in?
Innovacell's product category is Regenerative Medicine. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAAAKAC, Cell Therapy Manufacturing Services (GMP, autologous/allogeneic). Its NAICS code is 325414 and its SIC code is 2836.